COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
申请人:Plexxikon Inc.
公开号:US20160176865A1
公开(公告)日:2016-06-23
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
本文描述了在蛋白激酶上活性化合物,以及使用这些化合物治疗与蛋白激酶异常活动相关的疾病和状况的方法。
Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors
申请人:Bold Guido
公开号:US20080312248A1
公开(公告)日:2008-12-18
The invention relates to heteroaryl aryl ureas of the formula IA,
wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.
Pyrimidinyl aryl urea derivatives being FGF inhibitors
申请人:Novartis AG
公开号:US08293746B2
公开(公告)日:2012-10-23
The invention relates to heteroaryl aryl ureas of the formula IA,
wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.
Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors
申请人:Novartis AG
公开号:US20130030171A1
公开(公告)日:2013-01-31
The invention relates to heteroaryl aryl ureas of the formula IA,
wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.
Pyrirnidinyl aryl urea derivatives being FGF inhibitors
申请人:Novartis AG
公开号:US08759517B2
公开(公告)日:2014-06-24
The invention relates to heteroaryl aryl ureas of the formula IA,
wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.